Huiling Pharmaceutical Consulting (Shanghai)

Huiling Pharmaceutical Consulting (Shanghai) is the specialized research and regulatory subsidiary of Ferring Pharmaceuticals in China. Headquartered in Shanghai, the company oversees the clinical development, medical affairs, and registration of Ferring's global portfolio for the Chinese market, with a core focus on reproductive medicine, maternal health, urology, and gastroenterology. It manages key programs such as Rekovelle (follitropin delta) and Menopur (menotropins) for assisted reproduction, as well as treatments for prostate cancer and endocrine disorders. The entity serves as a critical link in Ferring's global R&D network, ensuring that innovative peptide-based and specialty therapies meet local regulatory standards and clinical needs.